Prediction of The Risk of Thromboembolic Complications in Patients with Atrial Fibrillation and Chronic Kidney Disease

Igamberdieva Ranokhon Shuhratkhodjaevna

doi:10.51699/cajmns.v6i4.3000

Igamberdieva Ranokhon Shuhratkhodjaevna Department of Internal Medicine, Nephrology and Hemodialysis, Tashkent State Medical University, assistant

DOI: https://doi.org/10.51699/cajmns.v6i4.3000

Keywords: Atrial Fibrillation, Chronic Kidney Disease, Thromboembolic Complications, Anticoagulant Therapy

Abstract

The risk of acute cerebrovascular accident and other systemic thromboembolic complications is very high in both atrial fibrillation and chronic kidney disease. However, it is currently unknown to what extent the prognostic value of these risks increases when these two conditions coexist.These risk factors lead to a sharp increase in disability and mortality, posing serious challenges to the healthcare system. The aim of the study is the early prediction of the risk of thromboembolic complications in patients with atrial fibrillation and chronic kidney disease. The study included 64 patients with atrial fibrillation and stage III CKD, divided into two subgroups based on anticoagulant therapy (warfarin or rivaroxaban). Anticoagulant doses were adjusted individually. The CHA2DS2-VASc score was used to assess the risk of thromboembolic complications. Patients were re-examined dynamically at months 3, 6, 9, and 12 of the study. Plasma creatinine levels in the warfarin group averaged 139.7±27.9 μmol/L at baseline, rising to 160.2±32.7 μmol/L (p<0.001) by month 12 of the study. In this group of patients, creatinine levels increased by an average of 20.6 μmol/L. In contrast, positive dynamics in renal filtration function were observed in the rivaroxaban group. Blood creatinine levels were 133.1±23.9 μmol/L at baseline and 139.3±25.1 μmol/L at month 12 of observation (p<0.05). Quarterly monitoring of blood creatinine in patients with AF and stage III CKD receiving rivaroxaban demonstrated an increase of an average of 6.2 μmol/L (p<0.001). Accordingly, a feasibility study analysis was also conducted in each subgroup, where 20.7% of cases were noted in the warfarin group (p<0.001) and 8.6% of cases in the rivaroxaban group. A high frequency of feasibility study was recorded in the group with CKD and AF (OR-2.1, 95% CI 0.60-7.36). In patients with AF and CKD treated with warfarin, TECs occurred in 20.7% of cases, which is significantly lower than in patients taking NOACs (8.6%, p<0.001). The study also identified a negative impact of warfarin on renal filtration function.

References

T. N. Lea-Henry, J. E. Carland, S. L. Stocker et al., “Clinical pharmacokinetics in kidney disease: Fundamental principles,” Clin. J. Am. Soc. Nephrol., vol. 13, no. 7, pp. 1085–1095, Jul. 2018, doi: 10.2215/CJN.00340118.

J. Tran, C. Shaffelburg, E. Phelan, H. Neville et al., “Community pharmacists’ perspectives on assessing kidney function and medication dosing for patients with advanced chronic kidney disease: A qualitative study using the theoretical domains framework,” Can. Pharm. J. (Ott)., vol. 156, no. 5, pp. 272–281, Sep.–Oct. 2023, doi: 10.1177/17151635231176530.

W. Ageno, A. S. Gallus, A. Wittkowsky et al., “Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2 Suppl., pp. e44S–e88S, Feb. 2021, doi: 10.1378/chest.11-2292.

L. Golbin, C. Vigneau, G. Touchard et al., “Warfarin-related nephropathy induced by three different vitamin K antagonists: Analysis of 13 biopsy-proven cases,” Clin. Kidney J., vol. 10, no. 3, pp. 381–388, Jun. 2017, doi: 10.1093/ckj/sfw133.

J. Domienik-Karłowicz, O. Tronina, W. Lisik, M. Durlik, and P. Pruszczyk, “The use of anticoagulants in chronic kidney disease: Common point of view of cardiologists and nephrologists,” Cardiol. J., vol. 27, no. 6, pp. 868–874, 2020, doi: 10.5603/CJ.a2019.0025.

S. V. Brodsky, T. Nadasdy, B. H. Rovin et al., “Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate,” Kidney Int., vol. 80, no. 2, pp. 181–189, Jul. 2011, doi: 10.1038/ki.2011.44.

J. A. Vílchez, P. Gallego, and G. Y. Lip, “Safety of new oral anticoagulant drugs: A perspective,” Ther. Adv. Drug Saf., vol. 5, no. 1, pp. 8–20, Feb. 2024, doi: 10.1177/2042098613507945.

R. Shah and M. R. Patel, “Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice,” Ther. Adv. Cardiovasc. Dis., vol. 11, no. 3, pp. 105–120, Mar. 2017, doi: 10.1177/1753944716663156.

J. L. Halperin, G. J. Hankey, D. M. Wojdyla et al., “Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET AF trial,” Circulation, vol. 130, no. 2, pp. 138–146, Jul. 2014, doi: 10.1161/CIRCULATIONAHA.113.005008.

W. T. Zeng, X. T. Sun, K. Tang, W. Y. Mei, L. J. Liu, Q. Xu, and Y. J. Cheng, “Risk of thromboembolic events in atrial fibrillation with chronic kidney disease,” Stroke, vol. 46, no. 1, pp. 157–163, 2015.

P. T. Matusik, W. J. Leśniak, Z. Heleniak, and A. Undas, “Thromboembolism and bleeding in patients with atrial fibrillation and stage 4 chronic kidney disease: Impact of biomarkers,” Pol. Heart J. (Kardiol. Pol.), vol. 79, no. 10, pp. 1086–1092, 2021.

Y. C. Lau, M. Proietti, E. Guiducci, A. D. Blann, and G. Y. Lip, “Atrial fibrillation and thromboembolism in patients with chronic kidney disease,” J. Am. Coll. Cardiol., vol. 68, no. 13, pp. 1452–1464, 2016.

L. I. Si-Tong, C. Jiang, H. E. Liu, Q.-F. Li, Z. Ding, J.-H. Wu, et al., “Chronic kidney disease and risks of adverse clinical events in patients with atrial fibrillation,” J. Geriatr. Cardiol. vol. 18, no. 11, pp. 867–873, 2021.

L. R. Zelnick, M. G. Shlipak, E. Z. Soliman et al., “Prediction of incident atrial fibrillation in chronic kidney disease: The chronic renal insufficiency cohort study,” Clin. J. Am. Soc. Nephrol., vol. 16, no. 7, pp. 1015–1024, 2021.

M. Magnocavallo, A. Bellasi, M. V. Mariani et al., “Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease: Role of anticoagulation therapy,” J. Clin. Med., vol. 10, no. 1, p. 83, 2020.

R. Providência, E. Marijon, S. Boveda et al., “Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation,” Am. J. Cardiol., vol. 114, no. 4, pp. 646–653, 2014.